RecruitingNot ApplicableNCT07464808

Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management

Sponsor

Ain Shams University

Enrollment

25 participants

Start Date

Nov 28, 2025

Study Type

INTERVENTIONAL

Conditions

Venous Thromboembolic Event

Summary

This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay and follow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay for people with venous thromboembolic event. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERfollow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay

follow up vte incidence and routine clexan dose modification

OTHERfollow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay

follow up of vte incidence with no routine dose modification unless indicated

Locations(1)

Ain Shams University

Cairo, Abbassia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07464808

Related Trials

Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)

NCT07372716